I don't think we can count on ROW anytime soon. Titan is meeting with the EMA, which means they are pursuing approval in Europe, probably in an effort to maximize their negotiating position in a license deal. Still, very time consuming.
It really just depends on the rate of adoption. I've searched for any hints online, but found practically nothing. If each one of the 2,342 trained prescribed just one implant in the 3Q, I think we would skyrocket.
News 
Market Data 
Discover 
AI
